Will Pharma End Up Paying For The Infrastructure Bill?
Executive Summary
Or can industry thread the donut hole and prevent government price negotiations from becoming a part of the legislative tsunami?
You may also be interested in...
Pharma’s Upcoming Messaging Battles In US Pricing Debate Foreshadowed In CBO Report
Our infographic offers the top takeaways from Congressional Budget Office report that says lower drug prices would decrease industry’s spend on research and development, while rejecting claim that costs of R&D set or impact a particular medicines price.
Biden Administration Will Back New Health Research Contracting Agency
Upcoming budget proposal likely to include a proposal for funding of a DARPA-like contracting entity. Any focus on innovations and breakthroughs is likely welcome news for industry – though perhaps not the message that government is taking on work that drug companies can’t or won’t do.
FDA Neuroscience Director Dunn's Appearance At Tanezumab AdComm Confirms Neurology Office Is Intact
Dunn’s participation at the panel meeting ended speculation that he left the US FDA.